The impact of pharmacogenomics on a pharmacy and therapeutic committee's formulary system management: An opinion of the pharmacokinetics/pharmacodynamics/pharmacogenomics practice and Research Network for the American College of Clinical Pharmacy DOI Creative Commons
Jacob T. Brown, Micheline Andel Goldwire, Amanda Massmann

et al.

JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 14, 2024

Abstract Pharmacogenomic (PGx) considerations are increasingly influencing health system formularies, prompting Pharmacy and Therapeutics (P&T) committees to integrate genetic insights into their decision‐making processes. This can be the case in several clinical scenarios, including (1) Prioritizing use of lower‐cost drugs, where PGx testing is applied guide medications when appropriate, (2) Rescuing that effective majority individuals but were removed from formulary because harm a subset with specific phenotype, (3) Improving medication safety by utilizing testing/results initiation reduced drug doses or alternative therapy patients at‐risk genotypes, (4) Restricting high‐cost drugs most likely respond based on genotype. The primary objective this PRN opinion piece describe how impacts management, challenges opportunities arise precision medicine approaches prescribing.

Language: Английский

Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US DOI

Tabea Tracksdorf,

D. Max Smith,

Skyler Pearse

et al.

Supportive Care in Cancer, Journal Year: 2024, Volume and Issue: 32(8)

Published: July 9, 2024

Language: Английский

Citations

3
Receptor Pharmacogenomics: Deciphering Genetic Influence on Drug Response DOI Open Access
Sorina Andreea Anghel, Cristina-Elena Dinu-Pîrvu,

Mihaela-Andreea Costache

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(17), P. 9371 - 9371

Published: Aug. 29, 2024

The paradigm “one drug fits all” or dose will soon be challenged by pharmacogenetics research and application. Drug response—efficacy safety—depends on interindividual variability. current clinical practice does not include genetic screening as a routine procedure account for variation. Patients with the same illness receive treatment, yielding different responses. Integrating pharmacogenomics in therapy would provide critical information about how patient respond to certain drug. Worldwide, great efforts are being made achieve personalized therapy-based approach. Nevertheless, global harmonized guideline is still needed. Plasma membrane proteins, like receptor tyrosine kinase (RTK) G protein-coupled receptors (GPCRs), ubiquitously expressed, involved diverse array of physiopathological processes. Over 30% drugs approved FDA target GPCRs, reflecting importance assessing variability among individuals who treated these drugs. Pharmacogenomics transmembrane protein dynamic field profound implications precision medicine. Understanding variations provides framework optimizing therapies, minimizing adverse reactions, advancing healthcare.

Language: Английский

Citations

2
Public preferences for pharmacogenetic testing in the NHS: Embedding a discrete choice experiment within service design to better meet user needs DOI Creative Commons
John McDermott, Videha Sharma, William G. Newman

et al.

British Journal of Clinical Pharmacology, Journal Year: 2024, Volume and Issue: 90(7), P. 1699 - 1710

Published: April 14, 2024

Genetic testing can be used to improve the safety and effectiveness of commonly prescribed medicines-a concept known as pharmacogenetics. This study aimed quantify members UK public's preferences for a pharmacogenetic service delivered in primary care National Health Service.

Language: Английский

Citations

1
Strategies for DPYD Testing Prior to Fluoropyrimidine Chemotherapy in the United States DOI Creative Commons

Tabea Tracksdorf,

D. Max Smith,

Skyler Pearse

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: May 14, 2024

Abstract Purpose Patients with dihydropyrimidine dehydrogenase (DPD) deficiency are at high risk for severe and fatal toxicity from fluoropyrimidine (FP) chemotherapy. Pre-treatment DPYD testing is standard of care in many countries, but not the United States (US). This survey assessed pre-treatment approaches US to identify best practices broader adoption. Methods From August October 2023, a 22-item QualtricsXM was sent institutions clinicians known conduct broadly distributed through relevant organizations social networks. Responses were analyzed using descriptive analysis. Results 24 unique sites that have implemented or detailed implementation plan place analyzed. Only 33% ordered all FP-treated patients; remaining sites, patients tested depending on disease characteristics clinician preference. Almost 50% depend individual remember order without assistance electronic alerts workflow reminders. most often conducted by commercial laboratories least 4 5 variants considered clinically actionable. Approximately 90% reported receiving results within 10 days ordering. Conclusion Implementing into routine clinical practice feasible requires coordinated effort among healthcare team. These will be used develop adoption prevent cancer FP

Language: Английский

Citations

0
The impact of pharmacogenomics on a pharmacy and therapeutic committee's formulary system management: An opinion of the pharmacokinetics/pharmacodynamics/pharmacogenomics practice and Research Network for the American College of Clinical Pharmacy DOI Creative Commons
Jacob T. Brown, Micheline Andel Goldwire, Amanda Massmann

et al.

JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 14, 2024

Abstract Pharmacogenomic (PGx) considerations are increasingly influencing health system formularies, prompting Pharmacy and Therapeutics (P&T) committees to integrate genetic insights into their decision‐making processes. This can be the case in several clinical scenarios, including (1) Prioritizing use of lower‐cost drugs, where PGx testing is applied guide medications when appropriate, (2) Rescuing that effective majority individuals but were removed from formulary because harm a subset with specific phenotype, (3) Improving medication safety by utilizing testing/results initiation reduced drug doses or alternative therapy patients at‐risk genotypes, (4) Restricting high‐cost drugs most likely respond based on genotype. The primary objective this PRN opinion piece describe how impacts management, challenges opportunities arise precision medicine approaches prescribing.

Language: Английский

Citations

0